Teva focus of FTC investigation over inhaler patents

Federal Trade Commission

hapabapa

The FTC has begun an investigation of Teva Pharmaceutical (NYSE:TEVA) over its apparent refusal to withdraw patents related to its asthma and COPD inhalers that the agency argues is delaying generic competition.

The agency has issued a civil investigative demand

Leave a Reply

Your email address will not be published. Required fields are marked *